Hcyb1

Overview

Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A ( IC 50 =0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Phosphodiesterase (PDE)

Product Information

• Catalog No.: HY-132993
• CAS No.: 2988566-71-6
• Molecular Formula: C24H20N4O
• Molecular Weight: 380.44
• Purity: 98.20%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution
• Availability: In-stock

Source

Original product source